M. M. Andrade-campos, Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With 90Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience, Clinical Lymphoma Myeloma and Leukemia, vol.15, issue.8, pp.464-471, 2015.
DOI : 10.1016/j.clml.2015.02.025

. Anon, Radioimmunotherapy effective first-line treatment for non-Hodgkin's lymphoma, Oncology, vol.14, issue.7, pp.1009-1039, 2000.

I. Aurer, 90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab, Lijec. Vjesn, vol.128, pp.7-8, 2006.

I. Azinovic, Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies, Cancer Immunology, Immunotherapy, vol.3, issue.Suppl 3, pp.1451-1458, 2006.
DOI : 10.1007/s00262-006-0148-4

M. Bienert, Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin???s lymphoma: initial experience, European Journal of Nuclear Medicine and Molecular Imaging, vol.16, issue.10, pp.1225-1233, 2005.
DOI : 10.1007/s00259-005-1770-7

C. Bodet-milin, Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography, Haematologica, vol.93, issue.3, pp.390-397, 2008.
DOI : 10.3324/haematol.10591

F. Buchegger, Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with 131I-Tositumomab Remain in Complete Remission, Journal of Nuclear Medicine, vol.52, issue.6, pp.896-900, 2011.
DOI : 10.2967/jnumed.111.087460

T. Cazaentre, Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma, European Journal of Nuclear Medicine and Molecular Imaging, vol.29, issue.suppl, pp.494-504, 2010.
DOI : 10.1007/s00259-009-1275-x

B. D. Cheson, Revised Response Criteria for Malignant Lymphoma, Journal of Clinical Oncology, vol.25, issue.5, pp.579-586, 2007.
DOI : 10.1200/JCO.2006.09.2403

B. D. Cheson, The Role of Radioimmunotherapy with Yttrium-90 Ibritumomab Tiuxetan in the Treatment of Non-Hodgkin Lymphoma, BioDrugs, vol.19, issue.4, pp.309-322, 2005.
DOI : 10.2165/00063030-200519050-00004

P. S. Conti, The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry, J. Nucl. Med, issue.11, pp.46-1812, 2005.

S. J. Denardo, Prolonged Survival Associated with Immune Response in a Patient Treated with Lym-1 Mouse Monoclonal Antibody, Cancer Biotherapy & Radiopharmaceuticals, vol.13, issue.1, pp.1-12, 1998.
DOI : 10.1089/cbr.1998.13.1

A. M. Evens, The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial, Clinical Cancer Research, vol.15, issue.20, pp.6462-6471, 2009.
DOI : 10.1158/1078-0432.CCR-09-0905

F. Forrer, Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas, Journal of Nuclear Medicine, vol.54, issue.7, pp.1045-1052, 2013.
DOI : 10.2967/jnumed.112.115170

K. Fukuno, Y-ibritumomab tiuxetan for a hemodialysis patient with relapsed follicular lymphoma, Leukemia & Lymphoma, vol.44, issue.1, pp.2731-2733, 2013.
DOI : 10.1002/cncr.22617

A. S. Gokhale, Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy, International Journal of Radiation Oncology*Biology*Physics, vol.63, issue.1, pp.194-201, 2005.
DOI : 10.1016/j.ijrobp.2005.01.017

L. I. Gordon, Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study, Blood, vol.103, issue.12, pp.4429-4431, 2004.
DOI : 10.1182/blood-2003-11-3883

S. A. Gregory, Selecting patients for treatment with 90Y ibritumomab tiuxetan (zevalin), Seminars in Oncology, vol.30, pp.17-22, 2003.
DOI : 10.1053/j.seminoncol.2003.10.004

A. Grgic, Retrospective web-based multicenter evaluation of 18F-FDG-PET and CT derived predictive factors, Nuklearmedizin, vol.50, issue.1, pp.39-47, 2011.
DOI : 10.3413/nukmed-0322-10-06

K. Hanaoka, Heterogeneity of intratumoral (111)In-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin's lymphoma. EJNMMI Res, p.10, 2015.

K. Hohloch, Radioimmunotherapy Confers Long-Term Survival to Lymphoma Patients with Acceptable Toxicity: Registry Analysis by the International Radioimmunotherapy Network, Journal of Nuclear Medicine, vol.52, issue.9, pp.1354-1360, 2011.
DOI : 10.2967/jnumed.111.089920

K. Hohloch, Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network, European Journal of Nuclear Medicine and Molecular Imaging, vol.28, issue.Suppl 4, pp.1585-1592, 2014.
DOI : 10.1007/s00259-014-2758-y

S. J. Horning, Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab, Journal of Clinical Oncology, vol.23, issue.4, pp.712-719, 2005.
DOI : 10.1200/JCO.2005.07.040

A. Iagaru, S. S. Gambhir, and M. L. Goris, 90Y-Ibritumomab Therapy in Refractory Non-Hodgkin's Lymphoma: Observations from 111In-Ibritumomab Pretreatment Imaging, Journal of Nuclear Medicine, vol.49, issue.11, pp.49-1809, 2008.
DOI : 10.2967/jnumed.108.052928

A. Ibatici, Yttrium-Ibritumomab-Tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study, British Journal of Haematology, vol.20, issue.5, pp.710-716, 2014.
DOI : 10.1111/bjh.12695

T. M. Illidge, Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy, Blood, vol.113, issue.7, pp.1412-1421, 2009.
DOI : 10.1182/blood-2008-08-175653

T. M. Illidge, Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria, Journal of Clinical Oncology, vol.32, issue.3, pp.212-218, 2014.
DOI : 10.1200/JCO.2013.50.3110

T. M. Illidge, Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study, British Journal of Haematology, vol.10, issue.2, pp.274-282, 2016.
DOI : 10.1111/bjh.13954

H. A. Jacene, 18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy, Journal of Nuclear Medicine, vol.50, issue.1, pp.8-17, 2009.
DOI : 10.2967/jnumed.108.055376

J. M. Joyce, FDG PET CT Assessment of Treatment Response After Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy, Clinical Nuclear Medicine, vol.30, issue.8, pp.564-568, 2005.
DOI : 10.1097/01.rlu.0000170086.45627.99

W. Jurczak, Radioimmunotherapy in follicular lymphomas: a retrospective analysis of the Polish Lymphoma Research Group's (PLRG) experience, Nucl. Med. Rev. Cent. East. Eur, vol.10, issue.2, pp.91-97, 2007.

W. Jurczak, The use of Yttrium-90 Ibritumomab Tiuxetan ( 90 Y-IT) as a??consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation, Wsp????czesna Onkologia, vol.1, issue.1, pp.43-47, 2015.
DOI : 10.5114/wo.2015.50012

M. E. Juweid, Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma, Journal of Clinical Oncology, vol.25, issue.5, pp.571-578, 2007.
DOI : 10.1200/JCO.2006.08.2305

M. S. Kaminski, I]Anti-B1 (Anti-CD20) Antibody, New England Journal of Medicine, vol.329, issue.7, pp.459-465, 1993.
DOI : 10.1056/NEJM199308123290703

M. S. Kaminski, Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience, Blood, vol.96, issue.4, pp.1259-1266, 2000.

M. S. Kaminski, I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma, New England Journal of Medicine, vol.352, issue.5, pp.441-449, 2005.
DOI : 10.1056/NEJMoa041511

K. Kaneko, Does tumoral (111)In-ibritumomab accumulation correlate with therapeutic effect and outcome in relapsed or refractory low-grade B-cell lymphoma patients undergoing (90)Y-ibritumomab radioimmunotherapy?, Eur. Radiol, issue.12, pp.24-3191, 2014.

H. J. Kang, Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). Asia Pac, J. Clin. Oncol, vol.7, issue.2, pp.136-145, 2011.

N. S. Kapadia, J. M. Engles, and R. L. Wahl, In Vitro Evaluation of Radioprotective and Radiosensitizing Effects of Rituximab, Journal of Nuclear Medicine, vol.49, issue.4, pp.674-678, 2008.
DOI : 10.2967/jnumed.107.043752

S. J. Knox, Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma, Clin. Cancer Res, vol.2, issue.3, pp.457-470, 1996.

K. R. Lamborn, Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies, Clin. Cancer Res, vol.3, issue.8, pp.1253-1260, 1997.

M. F. Leahy and J. H. Turner, Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients, Blood, vol.117, issue.1, pp.45-52, 2011.
DOI : 10.1182/blood-2010-02-269753

M. F. Leahy, Multicenter Phase II Clinical Study of Iodine-131???Rituximab Radioimmunotherapy in Relapsed or Refractory Indolent Non-Hodgkin???s Lymphoma, Journal of Clinical Oncology, vol.24, issue.27, pp.4418-4425, 2006.
DOI : 10.1200/JCO.2005.05.3470

J. P. Leonard, Abbreviated Chemotherapy With Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab for Untreated Follicular Lymphoma, Journal of Clinical Oncology, vol.23, issue.24, pp.5696-5704, 2005.
DOI : 10.1200/JCO.2005.14.803

I. Lim, Prognostic Significance of Pretreatment 18F-FDG PET/CT in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Treated by Radioimmunotherapy Using 131I-Rituximab, Acta Haematologica, vol.130, issue.2, pp.74-82, 2013.
DOI : 10.1159/000346436

O. Linden, Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas, Clin. Cancer Res, vol.5, pp.3287-3291, 1999.

E. Lopci, FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study, Annals of Oncology, vol.21, issue.9, pp.1877-1883, 2010.
DOI : 10.1093/annonc/mdq024

E. Lopci, FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma, Q. J. Nucl. Med. Mol. Imaging, vol.54, issue.4, pp.436-441, 2010.

R. M. Macklis, B. A. Beresford, and J. L. Humm, Radiobiologic studies of low-dose???rate90y-lymphoma therapy, Cancer, vol.88, issue.S3, pp.966-973, 1994.
DOI : 10.1002/1097-0142(19940201)73:3+<966::AID-CNCR2820731332>3.0.CO;2-G

A. M. Maffione, Late FDG PET Normalization After Radioimmunotherapy in a Patient With Non-Hodgkin Lymphoma, Clinical Nuclear Medicine, vol.34, issue.11, pp.777-778, 2009.
DOI : 10.1097/RLU.0b013e3181b81c34

A. D. Mcquillan, W. B. Macdonald, and J. H. Turner, F-fluorodeoxyglucose positron emission tomography, Leukemia & Lymphoma, vol.114, issue.1, pp.1271-1277, 2015.
DOI : 10.1200/JCO.2006.09.2882

F. Morschhauser, Phase III Trial of Consolidation Therapy With Yttrium-90???Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma, Journal of Clinical Oncology, vol.26, issue.32, pp.5156-5164, 2008.
DOI : 10.1200/JCO.2008.17.2015

F. Morschhauser, 2013. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International: randomized, phase III First-LineIndolent trial, J. Clin. Oncol, issue.16, pp.31-1977

P. Multani, Development of Radioimmunotherapy for the Treatment of Non-Hodgkin???s Lymphoma, International Journal of Hematology, vol.44, issue.suppl, pp.401-410, 2002.
DOI : 10.1007/BF02982805

M. Nakagawa, Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma, Japanese Journal of Radiology, vol.22, issue.8, pp.642-647, 2012.
DOI : 10.1007/s11604-012-0103-6

H. J. Olney, -tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma, Leukemia & Lymphoma, vol.13, issue.12, pp.2754-2760, 2014.
DOI : 10.1016/j.ctrv.2008.07.005
URL : https://hal.archives-ouvertes.fr/hal-01021050

V. Prasad, The Withdrawal of Drugs for Commercial Reasons, JAMA Internal Medicine, vol.174, issue.12, pp.1887-1888, 2014.
DOI : 10.1001/jamainternmed.2014.5756

O. W. Press, Radiolabeled Antibody Therapy of Human B Cell Lymphomas, Adv. Exp. Med. Biol, vol.303, pp.91-96, 1991.
DOI : 10.1007/978-1-4684-6000-1_11

O. W. Press, Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016, J. Clin. Oncol, issue.3, pp.31-314, 2013.

O. W. Press, A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP-Rituximab versus CHOP + 131Iodine--Tositumomab, Clinical Cancer Research, vol.19, issue.23, pp.6624-6632, 2013.
DOI : 10.1158/1078-0432.CCR-13-1120

S. Rajguru, Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study, Clin. Adv. Hematol. Oncol, issue.8, pp.12-509, 2014.

J. Reiss, Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma, Leukemia & Lymphoma, vol.71, issue.1, pp.2870-2875, 2015.
DOI : 10.1200/JCO.2006.06.4618

C. W. Scholz, (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial, J. Clin. Oncol, issue.3, pp.31-308, 2013.

S. Shen, Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies, Cancer, vol.3, issue.S12, pp.2553-2557, 1997.
DOI : 10.1002/(SICI)1097-0142(19971215)80:12+<2553::AID-CNCR30>3.0.CO;2-9

S. Shen, Splenic Volume Change and Nodal Tumor Response in Non-Hodgkin's Lymphoma Patients after Radioimmunotherapy Using Radiolabeled Lym-1 Antibody, Cancer Biotherapy & Radiopharmaceuticals, vol.20, issue.6, pp.662-670, 2005.
DOI : 10.1089/cbr.2005.20.662

R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, 2015, CA: A Cancer Journal for Clinicians, vol.61, issue.3, pp.5-29, 2015.
DOI : 10.3322/caac.21254

K. Smith, Outcomes of Patients With Non-Hodgkin's Lymphoma Treated With Bexxar With or Without External-Beam Radiotherapy, International Journal of Radiation Oncology*Biology*Physics, vol.82, issue.3, pp.1122-1127, 2012.
DOI : 10.1016/j.ijrobp.2010.09.044

G. Storto, Y???Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non???Hodgkin Lymphoma, Radiology, vol.254, issue.1, pp.245-252, 2010.
DOI : 10.1148/radiol.09090603

M. Takahashi, Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy, Sci. World J, p.368947, 2014.
DOI : 10.1155/2014/368947
URL : http://doi.org/10.1155/2014/368947

K. Tobinai, Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma, Cancer Science, vol.21, issue.1, pp.158-164, 2009.
DOI : 10.1111/j.1349-7006.2008.00999.x
URL : http://doi.org/10.1111/j.1349-7006.2008.00999.x

N. Uike, Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era, International Journal of Hematology, vol.118, issue.4, pp.386-392, 2014.
DOI : 10.1007/s12185-014-1636-5

J. M. Vose, Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin???s Lymphomas, Journal of Clinical Oncology, vol.18, issue.6, pp.1316-1323, 2000.
DOI : 10.1200/JCO.2000.18.6.1316

J. M. Vose, Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation, Leukemia & Lymphoma, vol.104, issue.4, pp.683-690, 2007.
DOI : 10.3816/CLM.2004.n.028

J. Y. Wagner, Myeloablative Anti-CD20 Radioimmunotherapy +/- High-Dose Chemotherapy Followed by Autologous Stem Cell Support for Relapsed/Refractory B-Cell Lymphoma Results in Excellent Long-Term Survival, Oncotarget, vol.4, issue.6, pp.899-910, 2013.
DOI : 10.18632/oncotarget.1037

C. A. White, Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies, Blood, vol.87, issue.9, pp.3640-3649, 1996.

G. A. Wiseman, Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial, Blood, vol.99, issue.12, pp.4336-4342, 2002.
DOI : 10.1182/blood.V99.12.4336

T. E. Witzig, B-Cell Non-Hodgkin's Lymphoma, Journal of Clinical Oncology, vol.17, issue.12, pp.17-3793, 1999.
DOI : 10.1200/JCO.1999.17.12.3793

T. E. Witzig, Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin???s Lymphoma, Journal of Clinical Oncology, vol.20, issue.15, pp.3262-3269, 2002.
DOI : 10.1200/JCO.2002.11.017

T. E. Witzig, Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan, Cancer, vol.23, issue.9, pp.1804-1810, 2007.
DOI : 10.1002/cncr.22617